TACSTD2 and neoplasm: DM001 was conjugated to MMAE via a protease-cleavable linker to generate the DM001 bsADC, which showed more potent cell-killing capacity in EGFR/TROP2-positive cells than single-target positive cells and showed potent anti-tumor activity in lung and pancreatic cell line xenografts and PDXs [149].